



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



Aticaprant

Item No. 35464

CAS Registry No.: 1174130-61-0
Formal Name: 4-[4-[[[(2S)-2-(3,5-dimethylphenyl)-1-pyrrolidinyl]methyl]phenoxy]-3-fluoro-benzamide
Synonyms: CERC-501, JNJ-67953964, LY2456302
MF: C₂₆H₂₇FN₂O₂
FW: 418.5
Purity: ≥98%
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Aticaprant is supplied as a solid. A stock solution may be made by dissolving the aticaprant in the solvent of choice, which should be purged with an inert gas. Aticaprant is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide. The solubility of aticaprant in these solvents is approximately 3, 5, and 1 mg/ml, respectively.

Description

Aticaprant is a κ -opioid receptor (KOR) antagonist ($K_i = 0.807$ nM).¹ It is selective for KOR over the μ - and δ -opioid receptors (K_i s = 24 and 155 nM, respectively). Aticaprant reverses U-69593-induced decreases in nocifensive behavior in the formalin test in rats ($ED_{50} = 0.4$ mg/kg). It also reverses U-69593-induced disruptions in prepulse inhibition in rats in a dose-dependent manner. Aticaprant (10 mg/kg) reduces immobility time in the forced swim test in mice. It reduces alcohol self-administration and the progressive ratio breakpoint in rats when administered at a dose of 10 mg/kg.

Reference

1. Rorick-Kehn, L.M., Witkin, J.M., Statnick, M.A., *et al.* LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders. *Neuropharmacology* **77**, 131-144 (2014).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/12/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM